参松养心胶囊治疗心肌损伤疗效及对CK-MB、cTnT水平的影响

Protective Effect of Shensong Yangxin Capsule on Myocardial Injury and The Impact onLevels of CK-MB and cTnI

目的研究参松养心胶囊用于治疗心肌损伤的疗效及对心肌酶(CK-MB)和心肌钙蛋白I(cTnI)水平的影响。方法选取行经皮冠状动脉介入(PCI)术后冠心病患者120例随机分为两组各60例。对照组患者给予常规西医治疗方案,治疗组患者在对照组基础上给予参松养心胶囊,3粒/d,3次/d,10 d为1个疗程,连续治疗3个疗程。对比两组患者治疗后的临床疗效、血清CK-MB和cTnI等心肌损伤指标、血小板活化功能、血清炎性因子水平、血液流变学和不良反应发生率。结果经过治疗后,治疗组总有效率显著高于对照组(P<0.05)。两组患者在CK-MB和cTnI水平方面进行比较,治疗后显著低于治疗前(P<0.05);治疗组降低程度较大(P<0.05)。两组患者在PV、WBV、PAR和FIB水平方面进行比较,治疗后显著优于治疗前(P<0.05);治疗组改善程度优于对照组(P<0.05)。两组患者LVEDV和LVEF水平显著高于治疗前(P<0.05),LVESV水平显著低于治疗前(P<0.05);并且治疗组LVEDV和LVEF水平显著高于对照组(P<0.05);治疗组LVESV水平显著低于对照组(P<0.05)。两组患者在IL-6、CRP和TNF-α水平方面进行比较,治疗后显著低于治疗前(P<0.05);治疗组改降低程度较大(P<0.05)。结论采用参松养心胶囊用于治疗PCI术后冠心病患者,临床疗效较好,能够减轻心肌损伤。

Objective To study the protective effect of Shensong Yangxin Capsule on myocardial injury and the impact of myocardial enzymes(CK-MB)and myocardial calcium protein I(cTnI)levels.Methods 120 coronary artery intervention(PCI)patients with coronary heart disease after operationwere randomly divided into research group and the control group,60 cases in each.The control group was treated with conventional western medicine treatment.The treatment group was given intravenous drip on the basis of Shensong Yangxin Capsule,3 pills/d,3 times/d.Ten days was a course of treatment,totally 3 consecutive courses of treatment.The clinical efficacy,myocardial injury indexes such as CK-MB and cTnI,platelet activation function,serum inflammatory factor level,hemorheology and incidence of adverse reactions were compared between the two groups after treatment.Results After treatment,the total effective rate of the treatment group was significantly higher than that of the control group(P<0.05).The levels of CK-MB and cTnI in the two groups were significantly lower after treatment than those before treatment(P<0.05).The degree of reduction was significant in the treatment group(P<0.05).PV,WBV,PARand FIB levels were compared between the two groupsand were significantly better after treatment than those before treatment(P<0.05).The improvement degree of the treatment group was better than that of the control group(P<0.05).LVEDV and LVEF levels were significantly higher in the two groups than those before treatment(P<0.05),and LVESV levels were significantly lower than those before treatment(P<0.05).LVEDV and LVEF levels in the treatment group were significantly higher than those in the control group(P<0.05).The level of LVESV in the treatment group was significantly lower than that in the control group(P<0.05).Levels of IL-6,CRP and TNF-alpha in the two groups were significantly lower after treatment than those before treatment(P<0.05).The degree of reduction was significant in the treatment group(P<0.05).Conclusion Shensong Yangxin Capsule is effective on treating coronary heart disease patients after PCIand can reduce myocardial injury.